505 results on '"Seibold, James R."'
Search Results
102. Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument
103. Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier.
104. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
105. Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion
106. Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial
107. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study
108. Recombinant human anti–transforming growth factor Β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
109. Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease–related Interstitial Lung Diseases
110. Developing A Disease Activity And Therapeutic Response Index In Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Consensus On Domains
111. Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise
112. Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)
113. Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
114. Developing Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Disease
115. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
116. Reply
117. Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group
118. Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)
119. Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
120. Patient and Physician Agreement-- Disagreement on Disease Severity in Scleroderma
121. DOPPLER ECHOCARDIOGRAPHY OVERESTIMATES PULMONARY HYPERTENSION IN PATIENTS WITH SCLERODERMA INTERSTITIAL LUNG DISEASE
122. Scleroderma Lung Disease
123. Sexual Activity and Functioning in Female Scleroderma Patients
124. Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease
125. Clinical trials in systemic sclerosis: lessons learned and outcomes
126. Systemic sclerosis and related connective tissue diseases: present and future
127. Estrogens and Neuropeptides in Raynaud's Phenomenon
128. Systemic Sclerosis.
129. Screening for PAH in Scleroderma: Identifying Hallmarks of the Disease and Optimal Treatment Strategies
130. Clinical trials: types, design, and end-points
131. Critical tissue ischaemia in scleroderma: a note of caution
132. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.
133. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative.
134. Paradoxical progress in scleroderma
135. Rational use of calcium-channel antagonists in Raynaud??s phenomenon
136. Slow progress in scleroderma?
137. Serum antibody to retroviral gag proteins in systemic sclerosis
138. Are we any closer to understanding scleroderma?
139. Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis
140. Yohimbine Elimination in Normal Volunteers Is Characterized by Both One- and Two-Compartment Behavior
141. Effect of Obesity and Feeding on the Growth Hormone (GH) Response to the GH Secretagogue L-692,429 in Young Men1
142. Current status of and future strategies for disease modification in systemic sclerosis
143. Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers*
144. Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis
145. The bioavailability and nonlinear pharmacokinetics of MK-679 in humans
146. The treatment of Raynaud's phenomenon
147. Regulation of Ornithine Decarboxylase in the Kidney of Autoimmune Mice with the lpr Gene
148. Pharmacodynamics of MK-0963, a new 5α-reductase inhibitor: Effects on serum androgen concentrations
149. Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis.
150. Endothelial and fibroblastic activation in scleroderma: The myth of the “uninvolved skin”
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.